Promising broader patient access to critical medicines, biosimilars offer a more cost-effective alternative therapeutic option compared with originator products. With many patents for blockbuster” commercial biologics set to expire in the next few years, biopharma developers have become increasingly drawn to the biosimilars market.

Click for full article